This upward trend confirms the  appeal of a sector that combines structural growth, resilience, and high barriers to entry. While overall global M&A activity has moderated since the peaks reached in 2021, dermatology and cosmetics have continued to attract both strategic buyers and financial investors, consolidating their position as one of the most dynamic segments within the consumer and healthcare landscape.

According to data analyzed by Albia IMAP, Spain has also strengthened its role within the European market. The number of transactions increased from 13 deals in 2021 to 22 in 2025, representing a 69% growth in just four years. This progress positions the Spanish market among the most active in Europe and reflects the growing interest in domestic companies specializing in dermatology, dermopharmacy, cosmetics, fragrances, and personal care.

Fernando Cabos, Partner at Albia IMAP, notes: “Dermatology and cosmetics have consolidated their position as one of the most attractive sectors for corporate investment. The combination of sustained growth, innovation capacity, strong branding, and consolidation opportunities is driving an intense M&A activity. In addition, the increasing sophistication of the sector — from a scientific, commercial, and regulatory standpoint — favors companies with greater scale and differentiated capabilities, making acquisitions a key tool to accelerate growth and enhance competitiveness.”

The role of strategic buyers remains particularly relevant in Spain. In 2025, 59% of transactions were led by companies within the sector, while private equity investors accounted for the remaining 41%. This distribution highlights how companies are increasingly turning to inorganic growth to expand their portfolios, integrate technological and scientific capabilities, strengthen their positioning in high value-added segments, and accelerate international expansion.

The market’s dynamism is also driven by the industry’s strong growth outlook. Rising demand linked to wellbeing, personal care, and skin health, together with the convergence between cosmetics, dermatology, consumer health, and technology, is creating new opportunities for both strategic operators and investors. In a still fragmented market with significant economies of scale, corporate transactions continue to establish themselves as one of the main drivers of transformation and growth within the European sector.